Brief: MaaT Pharma FY Net Loss Widens To EUR 13.7 Million
March 30 (Reuters) - Maat Pharma SA MAAT.PA :
* FY REVENUE EUR 1.4 MILLION VERSUS EUR 972,000 YEAR AGO
* FY NET LOSS EUR 13.7 MILLION VERSUS LOSS EUR 9.0 MILLION
YEAR
AGO
* END-DEC CASH AND CASH POSITION AT EUR 35.2 MILLION
Source text for Eikon: ID:nBw1tQTcCa
Further company coverage: MAAT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026